Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/130541
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients |
Author: | Lee, A. Patterson, K.A. Tan, D.J. Wilson, M.E. Proudman, S.M. Stevens, W. Nikpour, M. Sahhar, J. Ngian, G.-S. Roddy, J. Roberts-Thomson, P.J. Walker, J.G. |
Citation: | Scandinavian Journal of Rheumatology, 2021; 50(6):469-474 |
Publisher: | Taylor & Francis |
Issue Date: | 2021 |
ISSN: | 0300-9742 1502-7732 |
Statement of Responsibility: | AYS Lee, KA Patterson, DJ Tan, ME Wilson, SM Proudman, W Stevens, M Nikpour, J Sahhar, G-S Ngian, J Roddy, PJ Roberts-Thomson, JG Walker |
Abstract: | Objective: We undertook a comprehensive cross-sectional analysis of a multicentred Australian cohort of systemic sclerosis (SSc) patients to evaluate the associations of anti-Ro52/TRIM21 with SSc pulmonary involvement. Method: The study included 596 patients from the Australian Scleroderma Cohort Study database whose anti-Ro52/TRIM21 status was known. Anti-Ro52/TRIM21 was measured via line immunoassay. Data on demographic variables, autoantibody profiles, presence of interstitial lung disease (ILD), presence of pulmonary arterial hypertension (PAH), oxygen saturation, Six-Minute Walk Test distance, Borg dyspnoea score, and lung function tests were extracted. SPSS software was used to examine associations using univariate and multivariate analyses. Results: Anti-Ro52/TRIM21 was present in 34.4% of SSc patients. In the cross-sectional analysis, anti-Ro52/TRIM21 was independently associated with PAH [odds ratio 1.75, 95% confidence interval (CI) 1.05–2.90], but not ILD or other surrogate measures of pulmonary involvement such as average patient oxygen saturation. The antibody, however, was also associated with a higher forced vital capacity/diffusing capacity of the lung for carbon monoxide ratio. Prospectively, anti-Ro52/TRIM21 was also associated with an increased risk of death in patients with SSc (hazard ratio 1.62, 95% CI 1.11–2.35), independent of confounding factors. The primary cause of death appeared to be related to PAH and/or ILD, and anti-Ro52/TRIM21 was associated with PAH-related complications. Conclusion: Anti-Ro52/TRIM21 was independently associated with PAH and mortality in SSc patients. Future longitudinal studies are recommended to investigate the timing and pathogenic mechanisms of this autoantibody in PAH. |
Keywords: | Humans Scleroderma, Systemic Autoantibodies Cohort Studies Cross-Sectional Studies Australia Pulmonary Arterial Hypertension |
Description: | Published online: 14 Apr 2021 |
Rights: | © 2021 Scandinavian Journal of Rheumatology Foundation |
DOI: | 10.1080/03009742.2021.1887927 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/GNT1176538 |
Published version: | http://dx.doi.org/10.1080/03009742.2021.1887927 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.